What Trioar does

Trioar (주식회사 트리오어) is a privately held South Korean biopharmaceutical company founded in 2021 and headquartered in Daejeon (유성구 갑천로 361-17), developing next-generation antibody-based platform technologies for cancer therapeutics. The company's core platforms — TROCAD™, a proprietary antibody engineering platform, and TROSIG™, a novel linker-toxin system — are designed to overcome the chronic limitation of low therapeutic index in antibody-based drugs by simultaneously improving drug delivery to tumor sites and reducing systemic toxicity. These platforms are applied across Antibody-Drug Conjugates (ADCs), immuno-oncology, and emerging modalities including Peptide-Drug Conjugates (PDCs). A third technology, ReleaDom, is filed/pending and targets the same delivery-and-toxicity problem. Trioar is venture-backed with approximately 41.5 billion KRW (~$31 million USD) in cumulative funding through Series B in July 2025, and operates with 11-50 employees.

Trioar runs a pure B2B licensing and co-development model targeting global pharmaceutical companies as anchor licensees and biotech firms as complementary co-development partners. Revenue mechanics follow a standard pharma licensing structure: upfront payments, development milestones, and tiered royalties on eventual product sales. The company's flagship commercial validation is a November 19, 2025 technology transfer and option agreement with Celltrion for the TROCAD platform, potentially worth over $350 million USD (approximately 5,220 억 won / ~522 billion KRW) including development milestones and sales royalties. Earlier co-development partnerships include a PDC joint development agreement with C-bios (씨바이오멕스, signed December 2021) and an antibody discovery collaboration with Y-Biologics (와이바이오로직스), both leveraging Trioar's linker-toxin technology.

Customer and partner composition skews toward a small set of high-value relationships: Celltrion (flagship), C-bios, Y-Biologics, and Daan Bio (다안바이오, ADC partnership announced November 17, 2025). Marketing is conducted through open innovation programs (e.g., the Seoul-BMS Innovation Square Challenge win in November 2023), industry conferences, and press relations around funding and partnership milestones. Trioar was selected as a Baby Unicorn by the Korean Ministry of SMEs and Startups in May 2023, providing eligibility for up to 17.3 billion KRW in government support. The CEO and co-founder, Woo Seong-ho (우성호, PhD from Ohio State University), previously led diabetes R&D at LG Life Sciences and was a founding member of LegoChem Biosciences (레고켐바이오), contributing to its KOSDAQ listing and technology transfer activity.

Name

Trioar

Legal name

주식회사 트리오어 (Trioar Inc.)

Website

https://trioar.co.kr

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Trioar is a South Korean biopharmaceutical company developing proprietary antibody (TROCAD) and linker-toxin (TROSIG) platforms to improve the therapeutic index of ADCs and immuno-oncology drugs, licensing its technology to global pharma partners including Celltrion.

Ownership category

akta.pro rank

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Technology Licensing: The company generates revenue through licensing its proprietary platforms (TROCAD, TROSIG) to pharmaceutical companies. The Celltrion deal includes development milestones and sales royalties, indicating a traditional pharma licensing model with upfront payments, milestone payments, and ongoing royalties on product sales.
2. Co-development and Partnership Revenue: Revenue from co-development agreements with pharmaceutical and biotech partners, including PDC development with C-bios and ADC development partnerships, potentially including research payments and milestone achievements

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Trioar is a biopharmaceutical research company that develops proprietary antibody-based platform technologies — the TROCAD antibody platform and the TROSIG linker-toxin system — to improve the therapeutic index of antibody-based therapies. These platforms are applied across antibody-drug conjugates (ADCs) and immuno-oncology modalities and are monetized through licensing agreements and co-development partnerships with global pharmaceutical and biotech companies.

Product overview

Trioar is an antibody-based platform development company offering a unified portfolio centered on two proprietary technologies: TROCAD™ (antibody platform) and TROSIG™ (linker-toxin system). These platforms work together to enhance the therapeutic index of antibody-based therapies by improving drug delivery to tumor microenvironments and enabling targeted cancer cell killing. The company applies these technologies across multiple therapeutic modalities including Antibody-Drug Conjugates (ADCs) and Immuno-oncology treatments, providing new treatment options for patients who could benefit from improved efficacy and reduced toxicity.

Differentiator

Problem solved

Functional benefit

Brands

• TROCAD™: Proprietary antibody platform developed by Trioar to improve drug delivery to tumor sites and enhance therapeutic efficacy by improving therapeutic index.
• TROSIG™

Products and services

• TROCAD TROCAD is a proprietary next-generation antibody platform technology designed to improve the therapeutic index of antibody-based therapies by enhancing drug delivery to tumor sites and reducing side effects. It is applicable to antibody-drug conjugates (ADCs) and immuno-oncology treatments and is licensed to pharmaceutical partners such as Celltrion.
• TROSIG TROSIG is a novel linker-toxin system for antibody-drug conjugates that enables rapid cancer cell death induction while improving drug stability and efficacy. The linker technology is highly stable in blood and releases drugs only under specific tumor microenvironment conditions, enabling improved safety and efficacy profiles in ADC applications.
• Antibody-Drug Conjugate (ADC) Development Programs Trioar's ADC programs combine tumor-specific antibodies with biologically active drugs/cytotoxic compounds connected through its proprietary TROSIG linkers, enhanced by the TROCAD antibody platform. These programs target cancer therapeutics for licensing and co-development with pharmaceutical and biotech partners.
• Immuno-Oncology Programs Trioar's immuno-oncology programs focus on developing cancer treatments that strengthen the patient's immune system to find and attack tumors, utilizing the TROCAD antibody platform for enhanced therapeutic efficacy across bispecific antibodies, immune checkpoint inhibitors, and tumor microenvironment targeting approaches.

Quantifiable outcome

• Therapeutic index improvement through simultaneous efficacy enhancement and toxicity reduction
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• CelltrionflagshipStrategic or Co-development Partner · 19 November 2025Celltrion secured an option to use Trioar's TROCAD antibody platform in a deal potentially worth over $350 million. The agreement includes development milestones and sales royalties. This partnership reflects Celltrion's expansion beyond biosimilars into antibody-based therapies and represents a major validation of Trioar's platform technology.
• CelltrionflagshipTechnology or Integration · 19 November 2025Technology transfer contract valued at approximately 5,220 billion KRW (Korean won), representing one of the largest biotech licensing deals involving Trioar's TROCAD platform technology.
• C-bios (씨바이오멕스)coreStrategic or Co-development Partner · 1 December 2021Joint development agreement for Peptide-Drug Conjugate (PDC) new drugs using C-bios's CUSTM peptide discovery platform and Trioar's SIGT linker-toxin technology. The partnership aims to develop 2 anticancer targets with PDC candidates within 2 years. Initial validation of platform technologies has been completed.
• Y-Biologics (와이바이오로직스)coreStrategic or Co-development PartnerJoint research partnership for new antibody discovery, utilizing Y-Biologics' antibody expertise combined with Trioar's platform technologies for enhanced therapeutic development.
• Daan Bio (다안바이오)minorStrategic or Co-development PartnerADC new drug development partnership announced November 2025, focusing on advancing antibody-drug conjugate therapeutics.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating ADCs that combine targeted antibodies with immune agonists. Comparable as an emerging immuno-oncology/ADC hybrid platform.
• LegoChem Biosciences: Korean biotech developing antibody-drug conjugate platform technologies including proprietary linkers and payloads. Highly comparable to Trioar as a Korean ADC platform licensor; Trioar's CEO was a founding member of LegoChemBio, directly connecting the two companies.
• ADC Therapeutics: Clinical and commercial-stage ADC company developing targeted antibody therapeutics for hematologic and solid tumors. Comparable to Trioar in ADC modality focus, with deeper pipeline maturity illustrating both opportunity and competitive pressure.
• Mersana Therapeutics: US-based clinical-stage biotech building ADC platforms (Dolasynthen, Immunosynthen) targeting improved therapeutic index. Comparable to Trioar as a platform-focused ADC company monetizing through partnerships and proprietary candidates.
• Heidelberg Pharma: German biotech developing ADCs based on proprietary amanitin payload and linker technology. Closely comparable to Trioar as a payload/linker platform licensor pursuing pharma partnerships.
• Pyxis Oncology: US biotech developing ADCs and immuno-oncology therapeutics with a focus on tumor-microenvironment biology. Comparable to Trioar's combined ADC plus immuno-oncology platform positioning.

Broad incumbents

• Seagen: Established ADC-focused biopharma (acquired by Pfizer) with multiple approved ADC products and large-pharma partnership infrastructure. Sets the upper-bound reference for ADC platform economics.
• ImmunoGen: Pioneer in ADC technology (now part of AbbVie) with approved ADC products and deep pharma partnerships. Represents the broad incumbent benchmark for ADC platform value capture.
• Daiichi Sankyo: Global pharma that developed the Enhertu ADC platform in partnership with AstraZeneca and has built an industry-leading ADC franchise. Represents the dominant large-pharma incumbent and a likely partner/licensee archetype for Trioar.

Emerging players

• Tubulis: Germany-based emerging ADC platform company focused on next-generation linkers and conjugation chemistry. Comparable emerging-stage European peer to Trioar's linker/payload platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trioar